Merck & Co bolsters hepatitis C pipeline with Idenix acquisition


US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion (£2.3 billion). The deal gives Merck access to three investigational drug candidates from Idenix’s pipeline, which it hopes will complement treatments being developed in-house.

The most advanced of Idenix’s compounds, samatasvir, inhibits the virus’ non-structural protein 5A, which is involved in replicating viral RNA. It is currently in Phase II clinical trials. The other two, IDX21437 and IDX21459, are nucleotide prodrugs based on uridine, designed to inhibit RNA replication. Both are in Phase I trials.

The high price Merck is willing to pay for these early-stage assets (more than triple the value of Idenix’s shares before the announcement) indicates the company’s confidence in the longevity of the hepatitis C market. It also shows Merck’s desire to compete with the likes of Gilead’s Sovaldi (sofosbuvir), which has made over $2 billion in sales in the first quarter of this year since its approval in December 2013, despite complaints about its high price. The possibility of an all-oral treatment that is effective across the full range of viral genotypes, as well as eliminating the side effects caused by combining drugs with interferon and/or ribavirin is a tantalising goal, but as more drugs are introduced, competition will eat away at the price premium each can charge.


Related Content

Merger fever sweeps pharma

10 September 2015 Business

news image

The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it...

Pills, prices and politics

17 December 2015 Business

news image

2015 saw the pharmaceutical industry clash with lawmakers

Most Commented

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels

Crawling chemical system acts as if it’s alive

24 May 2016 Research

news image

Intriguing globule that moves, eats and defecates